Chem & Bio Engineering· 2026Q1· Review
Plant RNA Virus-Based Expression Vectors for Sustainable Biomanufacturing: Viral Chassis, Process Performance, and Engineering Perspectives
- 0citations
- Q1SCImago
- 2026year
Short summary
Plant RNA virus-based vectors offer a rapid, scalable, and sustainable platform for recombinant protein production, enabling faster development and higher yields (up to ~5 g/kg fresh biomass) compared to stable transformation.
AI-generated from the title and abstract; the full text is not read.
Key points
- Plant RNA virus vectors enable rapid, scalable, and sustainable recombinant protein production.
- These platforms shorten development timelines and allow for high-copy amplification compared to stable transformation.
- Engineered viral systems can produce a wide range of products, including reporters, vaccine antigens, antibodies, and enzymes.
- Reported yields can reach approximately 5 g/kg fresh biomass, depending on vector architecture, host, and delivery.
- These systems are viewed as bioengineering platforms, emphasizing manufacturing speed, scalability, and yield determinants.
AI-generated from the title and abstract; the full text is not read.
Abstract
Abstract Plant RNA virus-based expression vectors are emerging as modular biological chassis for rapid, scalable, and sustainable production of recombinant proteins in plants. From a chemical and biological engineering perspective, these systems integrate upstream vector design, host selection, inoculation strategy, intracellular amplification, product accumulation, and downstream recovery into a flexible biomanufacturing workflow. Compared with stable transformation, RNA viral platforms shorten development timelines, enable high-copy amplification, and support deployment in whole plants, plant tissues, cell cultures, and specialized secretion systems. The studies reviewed here show that Potyviridae, Virgaviridae, Alphaflexiviridae, Tombusviridae, Bromoviridae, Secoviridae/Comoviridae, and emerging Kitaviridae-derived systems have been engineered to produce reporters, vaccine antigens, virus-like particles, antibodies, nanobodies, enzymes, therapeutic proteins, metabolic enzymes, genome-editing components, and agronomic regulators. Reported outputs span qualitative accumulation to process-relevant yields, including approximately 5 g/kg fresh biomass, 3-5 mg/g fresh weight, 30 -80% of total soluble protein, and hundreds of mg/kg fresh tissue, depending on vector architecture, host chassis, insert properties, and delivery mode. We discuss these platforms as bioengineering systems rather than only virological tools, emphasizing manufacturing speed, process scalability, product classes, yield determinants, purification and quality-control challenges, biosafety, and opportunities for synthetic biology, computer-aided vector optimization, and sustainable plant-based production.
The authors' abstract, as published at the source. Chem & Bio Engineering, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
BiotechnologyBiochemistry, Genetics and Molecular Biology